(a) whether it is a fact that the National Green Tribunal (NGT) has asked Government to make it certain that all orders relating to granting of environment clearance are uploaded on its website within seven days of approval;

(b) if so, the details thereof;

(c) whether it is also a fact that this will help the public to challenge the approval within the stipulated period of 30 days to be computed from the date on which approval is effectively communicated to the public; and

(d) if so, the steps taken by Government in this regard?

THE MINISTER OF STATE OF THE MINISTRY OF ENVIRONMENT AND FORESTS (SHRIMATI JAYANTHI NATARAJAN): (a) to (d) The National Green Tribunal (NGT), in its order dated 14th March, 2013, in case of MA No. 104 of 2012 has issued directions which, *inter-alia,* state that the Ministry of Environment and Forests (MoEF) shall, within seven days from the date of passing of the order of Environment Clearance, upload it on its website and ensure that the same is accessible and can be downloaded without any delay or impediment. It would remain so uploaded on website for a period of at least 90 days. The date on which the order of environmental clearance is communicated to the public at large, shall be the date from which the period of limitation shall be taken into account.

The environment clearances are uploaded on the Ministry's website within seven days of their issuance.

National scheme for free medicines to all

†*417. SHRI NARENDRA KUMAR KASHYAP: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) the present status of implementation of National Scheme for free medicines to all through Government health centres;

(b) whether all the States/Union Territories have submitted their reports regarding the expenditure incurred on the scheme and physical and financial progress made in respect of the targets;

(c) if so, the details thereof;

---

†Original notice of the question was received in Hindi.

(d) the estimated amount of the funds required for this purpose for the next three years;

(e) the details of plan for the purchase and continuous supply of medicines and the mechanism for the distribution of medicines; and

(f) the steps taken by Government to ensure that these benefits reach the targeted beneficiaries?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) to (f) With a view to providing affordable health care to the people by reducing their out of pocket expenses on medicines, the Central Government has envisaged to start an initiative for the free supply of essential medicines in public health facilities in the country during the Twelfth Five Year Plan. It would be a Centrally Sponsored Scheme funded by the Central Government with contributions from the States. This initiative will promote rational use of medicines. The initiative is based on the Tamil Nadu model where medicines are procured in bulk by the Tamil Nadu Medical Services Corporation (TNMSC), in generic name, directly from the manufacturers and supplied free of cost through an IT enabled supply chain management system to the public. States would be encouraged to set up TNMSC like institutions or use any existing institution with sufficient autonomy for bulk procurement of essential drugs in generic names directly from the manufacturers. The drugs are envisaged to be supplied by the district ware houses through an IT enabled supply chain management system. A sum of Rs. 16000 crore has been approved for the scheme for the Twelfth Plan period.

As regards the information to be received from the States and UTs, so far Assam, Dadra & Nagar Haveli, Goa, Gujarat, Haryana, Kerala, Nagaland, Odisha, Puducherry, Tamil Nadu, Tripura, West Bengal, Andaman and Nicobar Islands, Andhra Pradesh, Himachal Pradesh, Mizoram, Sikkim, Chandigarh, Chhattisgarh, Rajasthan, Daman and Diu and Delhi have furnished the requisite information.

Compliance mechanism for obtaining consent in clinical trials

*418. SHRI N.K. SINGH: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government has any compliance mechanism for ensuring that the informed consent of the subjects of clinical trials in India is obtained;